Samus Therapeutics is a privately held Boston-based biopharmaceutical company developing novel therapeutics targeting the epichaperome, a foundational protein complex emergent from multiple disease states, including cancer and neurological disorders, such as Alzheimer's, Parkinson's and chronic traumatic encephalopathy.